Role of 18F-choline PET/CT in biochemically relapsed prostate cancer after radical prostatectomy: Correlation with trigger PSA, PSA velocity, PSA doubling time, and metastatic distribution

Clinical Nuclear Medicine

Volumn 38, Issue 1, 2013, Pages

  Marzola, Maria Cristina ^a   Chondrogiannis, Sotirios ^a   Ferretti, Alice ^b   Grassetto, Gaia ^a   Rampin, Lucia ^a   Massaro, Arianna ^a   Castellucci, Paolo ^c   Picchio, Maria ^d   Al Nahhas, Adil ^e   Colletti, Patrick M ^f   Marcolongo, Adriano ^b   Rubello, Domenico ^a  

^a PET/CT Centre   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

18F choline PET CT; biochemical relapse; prostate cancer; radical prostatectomy

Indexed keywords

CHOLINE DERIVATIVE; CHOLINE F 18; IASOCHOLINE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROMETHYLCHOLINE;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; METABOLISM; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROSTATE TUMOR; RADIOGRAPHY; RECURRENT DISEASE; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHOLINE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECURRENCE;

EID: 84871654410     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e318266cc38     Document Type: Article

References (44)

1. Kessler B, Albertsen P. The natural history of prostate cancer. Urol Clin North Am. 2003;30:219-222.
2. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909-916. (Pubitemid 17147932)
3. Carvalhal GF, Smith DS, Mager DE, et al. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/ml or less. . 1999;161:83-89.
4. Loeb S, Catalona WJ. What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? Nat Clin Pract Urol. 2009; 6:68-69.
5. Van der Kwast TH, Lopes C, Santonja C, et al. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol. 2003;56:336-340. (Pubitemid 36566816)
6. Hara R, Jo Y, Fujii T, et al. Optimal approach for prostate cancer detection as initial biopsy: prospective randomized study comparing transperineal versus transrectal systematic 12-core biopsy. Urol. 2008;71:191-195. (Pubitemid 351282351)
7. Takenaka A, Hara R, Ishimura T, et al. A prospective randomized comparison of diagnostic efficiency between transperineal and transrectal 12-core prostate biopsy. Prostate Cancer Prostatic Dis. 2008;11:134-138. (Pubitemid 351676600)
8. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level 4.0 ng per milliliter. N Engl J Med. 2004;350:2239-2246.
9. CatalonaWJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostatespecific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279: 1542-1547. (Pubitemid 28233009)
10. Freedland SJ, Presti JC Jr, Amling CL, et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61:736-741. (Pubitemid 36384965)
11. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523. (Pubitemid 36132976)
12. Vickers AJ, Savage C, O'Brien MF, et al. Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol. 2009;27:398-403.
13. Hoh CK, Seltzer MA, Franklin J, et al. Positron emission tomography in urological oncology. J Urol. 1998;159:347-356. (Pubitemid 28049232)
14. Hofer C, Laubenbacher C, Block T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur Urol. 1999;36:31-35. (Pubitemid 29265277)
15. Liu IJ, Zafar MB, Lai YH, et al. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology. 2001;57:108-111. (Pubitemid 32065829)
16. 18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003;169: 1337-1340. (Pubitemid 36323779)
17. Ferretti A, Bellan E, Gava M, et al. Phantom study of the impact of reconstruction parameters on the detection of mini- and micro-volume lesions with a low dose PET/CT acquisition protocol. Eur J Radiol. 2012;81:3363-3370.
18. Svatek RS, Shulman M, Choudhary PK, et al. Critical analysis of prostatespecific antigen doubling time calculation methodology. Cancer. 2006;106: 1047-1153.
19. Khan MA, Carte HB, Epstein JB, et al. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer? J Urol. 2003;170:2274-2278. (Pubitemid 37413974)
20. Connolly JA, Shinohara K, Presti JC Jr, et al. Local recurrence after radical prostatectomy: characteristics in size, location, and relationship to prostatespecific antigen and surgical margins. Urology. 1996;47:225-231. (Pubitemid 26075278)
21. Shekarriz B, Upadhyay J,Wood DP Jr, et al. Vesicourethral anastomosis biopsy after radical prostatectomy: predictive value of prostate-specific antigen and pathologic stage. Urology. 1999;54:1044-1048.
22. Kramer S, Gorich J, Gottfried HW, et al. Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. Br J Radiol. 1997;70:995-999. (Pubitemid 27464198)
23. 18F- or 11C-choline. J Nucl Med. 2010;52:81-89.
24. National Cancer Institute, Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Prostate. http://seer.cancer.gov/statfacts/html/prost. html. Accessed Oct 26, 2011.
25. Choueiri TK, Dreicer R, Paciorek A, et al. A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy. J Urol. 2008;179:906-910.
26. Cher ML, Bianco FJ Jr, Lam JS, et al. Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. J Urol. 1998;160:1387-1391. (Pubitemid 29480523)
27. Gomez P, Manoharan M, Kim SS, et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: when is it indicated? BJU Int. 2004;94:299-302. (Pubitemid 39120167)
28. Okotie OT, Aronson WJ, Wieder JA, et al. Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. J Urol. 2004;171:2260-2264. (Pubitemid 38625447)
29. Rinnab L, Blumstein NM, Mottaghy FM, et al. (11)C-choline positron-emission tomography/computed tomography and transrectal ultrasonography for staging localized prostate cancer. BJU Int. 2007;99:1421-1426. (Pubitemid 47164799)
30. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [(11)C] choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging. 2008;35:18-23. (Pubitemid 350234152)
31. Reske SN, Blumstein NM, Glatting G. [(11)C]Choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2008;35:9-17. (Pubitemid 350234137)
32. Giovacchini G, Picchio M, Briganti A, et al. [11C]Choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010;184:938-943.
33. Giovacchini G, Picchio M, Coradeschi E, et al. Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging. 2010; 37:301-309.
34. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med. 2009;50:1394-1400.
35. Bertagna F, Abuhilal M, Bosio G, et al. Role of 11C-choline positron emission tomography/computed tomography in evaluating patients affected by prostate cancer with suspected relapse due to prostate-specific antigen elevation. Jpn J Radiol. 2011;29:394-404.
36. Giovacchini G, Picchio M, Scattoni V, et al. PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. Eur J Med Mol Imaging. 2010;37: 1106-1116.
37. Giovacchini G, Picchio M, Parra RG, et al. Prostate-specific antigen doubling time for prediction of 11C-choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med. 2012;37:325-331.
38. 18F]Fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Med Mol Imaging. 2006;33:1387-1398. (Pubitemid 44885404)
39. 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med. 2008;113:895-904.
40. Maffezzin M, Bossi A, Collette L. Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. Eur Urol. 2007;51:605-613. (Pubitemid 46097288)
41. Palma D, Tyldesley S, Pickles T. Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy. Prostate Cohort Outcomes Initiative. Cancer. 2008;112:1941-1948. (Pubitemid 351574069)
42. Petit JH, Chen MH, Loffredo M, et al. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer. 2006;107:2180-2185. (Pubitemid 44665652)
43. 18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. Eur J Nucl Med Mol Imaging. 2012;39: 271-282.
44. Castellucci P., Fuccio C., Rubello D., et al. Is there a role for 11C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild increase G1.5 ng/ml? Eur J Nucl Med Mol Imaging. 2011, 38, 55-63.